Senktide trifluoroacetate salt

C₄₀H₅₅N₇O₁₁S · xC₂HF₃O₂

841.97 (free base basis)

NA.77

Suc-Asp-Phe-MePhe-Gly-Leu-Met-NH2 trifluoroacetate salt

Senktide treatment in follicular phase goats enhances the liberation of luteinizing hormone (LH) and advance the time of ovulation. Senktide has the ability to suppress gonadotropin-releasing hormone (GnRH) transcription. Treatment with senktide stimulates c-Fos and improve activator protein-1 (AP-1) activity.
Senktide is a selective Neurokinin NK3 tachykinin receptor agonist. Neurokinins (tachykinins) are members of a family of at least three neuropeptides, substance P, neurokinin A, and neurokinin B (NKB), with each mediating their biological effects through binding to a preferred G-protein-coupled receptor termed NK1, NK2, or NK3, respectively. All three NK receptors are expressed in regions of the central nervous system that are related to emotion and cognition (i.e., amygdala and hippocampus) and have been linked to various degrees in psychiatric disorders. Neurokinin receptors, including NK3 receptors, are also expressed in the motor and sensory systems of the digestive tract.

100

≥95% (HPLC)

film

desiccated

colorless

wet ice

−20℃

1S/C40H55N7O11S/c1-24(2)19-28(37(55)45-27(36(41)54)17-18-59-4)44-33(49)23-42-39(57)31(21-26-13-9-6-10-14-26)47(3)40(58)30(20-25-11-7-5-8-12-25)46-38(56)29(22-35(52)53)43-32(48)15-16-34(50)51/h5-14,24,27-31H,15-23H2,1-4H3,(H2,41,54)(H,42,57)(H,43,48)(H,44,49)(H,45,55)(H,46,56)(H,50,51)(H,52,53)/t27-,28-,29-,30-,31-/m0/s1

HMHYXLVEFVGOPM-QKUYTOGTSA-N

500 μg in glass bottle

13 - Non Combustible Solids

WGK 3